Medical technology company neuro42 has secured undisclosed investments from serial strategic angel investor Karna D Shinde, marking his third round of investment in the company. This announcement comes as neuro42 recently received USFDA clearance for its innovative diagnostic MRI product, a significant milestone that paves the way for the commercialization of its cutting-edge technology later this year.

Specializing in portable MRI, robotics, and AI technologies, neuro42's diagnostic MRI machine focuses on imaging the brain and head, particularly in MR-guided interventions. This capability is poised to revolutionize the approach to complex and time-sensitive procedures such as brain tumor treatment and epilepsy management.

Karna D Shinde, expressing enthusiasm about the potential of neuro42's MRI technology, highlighted its transformative impact on challenging brain tumor cases. Meanwhile, Abhita Batra, Founder and Chief Strategy Officer of neuro42, emphasized the company's dedication to improving patient care through accessible neuroimaging tools.

With preparations underway for the launch of its product later this year, neuro42's MRI has already garnered positive feedback and substantial interest from healthcare facilities across various Indian states, including Telangana, Maharashtra, and Karnataka. The USFDA clearance underscores a significant milestone for neuro42, positioning the company as a leader in innovative neuroimaging solutions.